Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma (Q37701147)

22 August 2017

title

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma (English)

1 reference

22 August 2017

12

Robert J Motzer

1 reference

22 August 2017

4

Bernard Escudier

1 reference

22 August 2017

Dorothy A White

1

1 reference

22 August 2017

Philippe Camus

2

1 reference

22 August 2017

Masahiro Endo

3

1 reference

22 August 2017

Emiliano Calvo

5

1 reference

22 August 2017

Hideyuki Akaza

6

1 reference

22 August 2017

Hirotsugu Uemura

7

1 reference

22 August 2017

Euloge Kpamegan

8

1 reference

22 August 2017

Andrea Kay

9

1 reference

22 August 2017

Matthew Robson

10

1 reference

22 August 2017

Alain Ravaud

11

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

American Journal of Respiratory and Critical Care Medicine

22 August 2017

published in

1 reference

22 August 2017

volume

182

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

396-403

1 reference

Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Severe everolimus-associated pneumonitis in a renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Sirolimus-associated pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Interstitial pneumonitis associated with sirolimus in liver transplantation: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Pneumonitis associated with sirolimus: clinical characteristics, risk factors and outcome--a single-centre experience and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Patterns of pulmonary complications associated with sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Case report of a kidney transplant recipient converted to everolimus due to malignancy: resolution of bronchiolitis obliterans organizing pneumonia without everolimus discontinuation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Clinical expression of leflunomide-induced pneumonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200911-1720OC

10.1164/RCCM.200911-1720OC

21 January 2018

Identifiers

DOI

1 reference

release_sfhrwtnnebhcbeynoqvfc42sma

22 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/sfhrwtnnebhcbeynoqvfc42sma

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference